VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates

Group 1 - VistaGen Therapeutics reported a quarterly loss of $0.46 per share, which was better than the Zacks Consensus Estimate of a loss of $0.50, but worse than the loss of $0.22 per share from a year ago, indicating an earnings surprise of 8% [1] - The company posted revenues of $0.23 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 35%, and a decline from $0.41 million in the same quarter last year [2] - VistaGen shares have underperformed the market, losing about 7.1% since the beginning of the year compared to the S&P 500's gain of 2.9% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.59 on revenues of $0.36 million, and for the current fiscal year, it is -$1.85 on revenues of $0.77 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 27% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8]